Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Lainie P. Martin · SciRah

Researcher profile · Semantic Scholar

Lainie P. Martin

Share profile

Lainie P. Martin — researcher profile on SciRah

h-index: 39
Works: 121
Citations: 6,343

Most-cited papers

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
D. Armstrong, R. Alvarez, J. Bakkum-Gamez, L. Barroilhet +30 more
2021The Journal of the National Comprehensive Cancer Network621 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
D. Armstrong, Ronald D. Alvarez, F. Backes, J. Bakkum-Gamez +34 more
2022The Journal of the National Comprehensive Cancer Network372 citations
Semantic Scholar
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
J. Chan, M. Brady, R. Penson, Helen Q. Huang +11 more
2016New England Journal of Medicine328 citations Open access
Semantic Scholar
Ovarian cancer, version 1.2016: Clinical practice guidelines in oncology
R. Morgan, D. Armstrong, R. Alvarez, J. Bakkum-Gamez +28 more
2016223 citations Open access
Semantic Scholar
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
K. Moore, Lainie P. Martin, D. O'Malley, U. Matulonis +5 more
2017Journal of Clinical Oncology190 citations Open access
Semantic Scholar
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
K. Papadopoulos, L. Gluck, Lainie P. Martin, A. Olszanski +7 more
2017Clinical Cancer Research162 citations Open access
Semantic Scholar
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
R. Morgan, D. Armstrong, R. Alvarez, J. Bakkum-Gamez +28 more
2016The Journal of the National Comprehensive Cancer Network155 citations
Semantic Scholar
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma
S. Lheureux, M. Butler, B. Clarke, M. Cristea +21 more
2017JAMA Oncology153 citations Open access
Semantic Scholar
Uterine neoplasms, version 1.2014.
W. Koh, Benjamin E. Greer, N. Abu-Rustum, Sachin M. Apte +24 more
2014The Journal of the National Comprehensive Cancer Network148 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
Joyce Liu, A. Berchuck, F. Backes, Joshua M. Cohen +36 more
2024The Journal of the National Comprehensive Cancer Network138 citations
Semantic Scholar
Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines
R. Morgan, R. Alvarez, D. Armstrong, R. Burger +22 more
2013135 citations Open access
Semantic Scholar
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
Lainie P. Martin, J. Konner, K. Moore, S. Seward +6 more
2017Gynecologic Oncology134 citations Open access
Semantic Scholar
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
D. O'Malley, U. Matulonis, M. Birrer, Cesar M. Castro +9 more
2020Gynecologic Oncology127 citations
Semantic Scholar
A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma
R. Amaravadi, R. Schilder, Lainie P. Martin, M. Levin +3 more
2015Molecular Cancer Therapeutics126 citations Open access
Semantic Scholar
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
U. Matulonis, I. Vergote, F. Backes, Lainie P. Martin +6 more
2015Gynecologic Oncology125 citations
Semantic Scholar
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
P. Shah, S. Wethington, Cheyenne Pagan, N. Latif +18 more
2021Gynecologic Oncology109 citations Open access
Semantic Scholar
Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer.
C. Meeker, D. Geynisman, B. Egleston, M. Hall +7 more
2016Journal of Oncology Practice95 citations Open access
Semantic Scholar
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
K. Moore, Lainie P. Martin, D. O'Malley, U. Matulonis +4 more
2018Future Oncology91 citations
Semantic Scholar
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
Irene Braña, R. Berger, T. Golan, P. Haluska +15 more
2014British Journal of Cancer89 citations Open access
Semantic Scholar
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
S. Wethington, P. Shah, Lainie P. Martin, J. Tanyi +15 more
2023Clinical Cancer Research86 citations Open access
Semantic Scholar
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial
G. Falchook, Robert L. Coleman, A. Roszak, K. Behbakht +22 more
2019JAMA Oncology83 citations Open access
Semantic Scholar
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
K. Moore, D. O'Malley, I. Vergote, Lainie P. Martin +3 more
2018Gynecologic Oncology81 citations Open access
Semantic Scholar
Ovarian cancer, version 2.2013.
R. Morgan, R. Alvarez, D. Armstrong, R. Burger +22 more
2013The Journal of the National Comprehensive Cancer Network81 citations
Semantic Scholar
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
B. You, C. Purdy, L. Copeland, E. Swisher +16 more
2022Journal of Clinical Oncology68 citations Open access
Semantic Scholar
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
H. Gray, K. Bell-McGuinn, G. Fleming, M. Cristea +6 more
2018Gynecologic Oncology67 citations
Semantic Scholar
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine
U. Matulonis, M. Birrer, D. O'Malley, K. Moore +8 more
2018Clinical Cancer Research67 citations Open access
Semantic Scholar
Distress and financial distress in adult cancer patients: an age-based analysis
C. Meeker, Y. Wong, B. Egleston, M. Hall +5 more
2017The Journal of the National Comprehensive Cancer Network61 citations Open access
Semantic Scholar
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
B. Monk, M. Sill, J. Walker, C. Darus +7 more
2016Journal of Clinical Oncology61 citations Open access
Semantic Scholar
Phase II trial of vorinostat in advanced melanoma
N. Haas, I. Quirt, S. Hotte, E. Mcwhirter +10 more
2014Investigational new drugs57 citations
Semantic Scholar
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer
Hanqing Liu, F. Xiao, I. Serebriiskii, S. O'Brien +7 more
2013Clinical Cancer Research52 citations Open access
Semantic Scholar
Safety Lead-In of the MEK Inhibitor Trametinib in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent Endometrial Cancer: An NRG Oncology/GOG Study
S. Westin, M. Sill, R. Coleman, S. Waggoner +11 more
2019Gynecologic Oncology39 citations Open access
Semantic Scholar
Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?
M. Birrer, I. Betella, Lainie P. Martin, K. Moore
2019The Oncologist38 citations Open access
Semantic Scholar
Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A Phase II trial (CTEP 7190/Mel47)
C. Slingluff, G. Petroni, Kerrington R. Molhoek, D. Brautigan +16 more
2013Clinical Cancer Research31 citations Open access
Semantic Scholar
Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer.
N. Senzer, P. LoRusso, Lainie P. Martin, R. Schilder +6 more
201328 citations
Semantic Scholar
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors
M. Zibelman, A. MacFarlane, K. Costello, T. McGowan +17 more
2023Nature Communications27 citations Open access
Semantic Scholar
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study.
U. Matulonis, K. N. Moore, Lainie P. Martin, I. Vergote +5 more
2018Annals of Oncology26 citations Open access
Semantic Scholar
Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.
A. Oaknin, L. Fariñas-Madrid, C. García-Durán, Lainie P. Martin +11 more
2023Journal of Clinical Oncology24 citations
Semantic Scholar
Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.
S. Wethington, P. Shah, Lainie P. Martin, J. Tanyi +13 more
202124 citations
Semantic Scholar
CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: an ACRIN and GOG study
C. Ng, Zheng Zhang, Susanna I. Lee, H. Marques +13 more
2017Clinical Cancer Research22 citations Open access
Semantic Scholar
First-inHuman Study of AMG 820 , a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody , in Patients with Advanced Solid Tumors
K. Papadopoulos, L. Gluck, Lainie P. Martin, A. Olszanski +7 more
201721 citations
Semantic Scholar
[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a pilot study
A. Pantel, Sarah B Gitto, M. Makvandi, Hyoung Kim +17 more
2022Clinical Cancer Research19 citations Open access
Semantic Scholar
Cervical cancer: Clinical practice guidelines in oncology
Benjamin E. Greer, W. Koh, N. Abu-Rustum, Sachin M. Apte +20 more
201318 citations
Semantic Scholar
Phase II study of weekly PM00104 (ZALYPSIS®) in patients with pretreated advanced/metastatic endometrial or cervical cancer
Lainie P. Martin, C. Krasner, Teresa L. Rutledge, Manuel Luque Ibañes +4 more
2013Medical Oncology15 citations
Semantic Scholar
NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Ovarian Cancer, Version 2.2020
D. Armstrong, R. Alvarez, J. Bakkum-Gamez, L. Barroilhet +31 more
202114 citations
Semantic Scholar
Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients
U. Matulonis, K. Moore, Lainie P. Martin, I. Vergote +5 more
2018Gynecologic Oncology14 citations
Semantic Scholar
A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.
S. Lheureux, M. Butler, B. Clarke, M. Cristea +16 more
201414 citations
Semantic Scholar
Utilization and survival outcomes of sequential, concurrent and sandwich therapies for advanced stage endometrial cancers by histology.
E. Ko, C. Brensinger, L. Cory, R. Giuntoli +6 more
2020Gynecologic Oncology13 citations
Semantic Scholar
Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovaria
D. O'Malley, K. Moore, I. Vergote, Lainie P. Martin +6 more
201713 citations
Semantic Scholar
Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
D. Nasioudis, N. Latif, E. Ko, L. Cory +4 more
2023Gynecologic Oncology12 citations
Semantic Scholar
Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage
Dhara Patel, Elizabeth Handorf, M. von Mehren, Lainie P. Martin +1 more
2019Sarcoma12 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. O'Malley×13
Invite
D. O'Malley — researcher profile on SciRah
U. Matulonis×13
Invite
U. Matulonis — researcher profile on SciRah
M. Birrer×12
Invite
M. Birrer — researcher profile on SciRah
D. Armstrong×10
Invite
D. Armstrong — researcher profile on SciRah

×10

Invite

K. Moore — researcher profile on SciRah

Invite

H. Gray — researcher profile on SciRah

Invite

S. Remmenga — researcher profile on SciRah

D. Gershenson×8

Invite

D. Gershenson — researcher profile on SciRah

Invite

A. Hakam — researcher profile on SciRah

Invite

K. Behbakht — researcher profile on SciRah

Lee-may Chen×7

Invite

Lee-may Chen — researcher profile on SciRah

Invite

T. Werner — researcher profile on SciRah